Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? - PubMed (original) (raw)

Clinical Trial

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure?

Paul R Kalra et al. Int J Cardiol. 2002 Oct.

Abstract

The last two decades have seen major advances in the treatment of chronic heart failure, primarily as a result of therapeutic manipulation of activated neurohormonal systems. Despite this progress, many patients still suffer significant morbidity and premature death. Antagonism of the biological effects of endothelin, a potent vasoconstrictor, represents a further potential target. To date, positive results from animal models of heart failure have not been translated into clinical practice, perhaps as a consequence of the high doses of drug used. The ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study evaluated the effects of low dose bosentan, a non-selective endothelin receptor antagonist, in patients with severe heart failure (left ventricular ejection fraction <35%, New York Heart Association class IIIb-IV). A total of 1,613 patients were randomized to receive either bosentan (125 mg twice a day) or placebo. The preliminary results were presented at the 51st Annual Scientific Session of the American College of Cardiology (17-20 March 2002, Atlanta, GA, USA). The primary endpoint of all-cause mortality or hospitalization for heart failure was reached in 321/808 patients on placebo and 312/805 receiving bosentan. Treatment with bosentan appeared to confer an early risk of worsening heart failure necessitating hospitalization, as a consequence of fluid retention. It has been suggested that further studies using even lower doses of bosentan or more aggressive concomitant diuretic therapy may avoid this adverse effect. The results from the ENABLE study have, however, thrown further doubt on the potential benefits of non-specific endothelin receptor blockade in heart failure.

PubMed Disclaimer

Cited by

Pulmonary Hypertension in the Era of Mechanical Circulatory Support.
Krishnamurthy Y, Cooper LB, Parikh KS, Felker GM, Milano CA, Rogers JG, Hernandez AF, Patel CB. Krishnamurthy Y, et al. ASAIO J. 2016 Sep-Oct;62(5):505-12. doi: 10.1097/MAT.0000000000000408. ASAIO J. 2016. PMID: 27442856 Free PMC article. Review.
Intersection of Pulmonary Hypertension and Right Ventricular Dysfunction in Patients on Left Ventricular Assist Device Support: Is There a Role for Pulmonary Vasodilators?
Sparrow CT, LaRue SJ, Schilling JD. Sparrow CT, et al. Circ Heart Fail. 2018 Jan;11(1):e004255. doi: 10.1161/CIRCHEARTFAILURE.117.004255. Circ Heart Fail. 2018. PMID: 29321132 Free PMC article. Review.
Effects of Fasudil on Patients with Pulmonary Hypertension Associated with Left Ventricular Heart Failure with Preserved Ejection Fraction: A Prospective Intervention Study.
Zhang X, Zhang X, Wang S, Luo J, Zhao Z, Zheng C, Shen J. Zhang X, et al. Can Respir J. 2018 Mar 26;2018:3148259. doi: 10.1155/2018/3148259. eCollection 2018. Can Respir J. 2018. PMID: 29785232 Free PMC article.
Pulmonary hypertension in left heart disease.
Guazzi M, Galiè N. Guazzi M, et al. Eur Respir Rev. 2012 Dec 1;21(126):338-46. doi: 10.1183/09059180.00004612. Eur Respir Rev. 2012. PMID: 23204122 Free PMC article. Review.
Pulmonary hypertension with left-sided heart disease.
Guazzi M, Arena R. Guazzi M, et al. Nat Rev Cardiol. 2010 Nov;7(11):648-59. doi: 10.1038/nrcardio.2010.144. Epub 2010 Oct 5. Nat Rev Cardiol. 2010. PMID: 20924360 Review.

Do results of the ENABLE (Endothelin Antagonist Bosentan for Lowering Cardiac Events in Heart Failure) study spell the end for non-selective endothelin antagonism in heart failure? - PubMed (original) (raw)